Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Eclutatug, an antibody targeting CLDN1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ciletatug, an antibody targeting Claudin 18.2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Brivestobart, an antibody targeting LAG-3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ulocuplumab, an antibody targeting CXCR4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Letolizumab, an antibody targeting CD40LG.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zampilimab, an antibody targeting TGM2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vofatamab, an antibody targeting FGFR3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tilogotamab, an antibody targeting TNFRSF10B.

2026 Thanatophoric dysplasia strategy: epidemiology, FGFR3 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Hypochondroplasia strategy: epidemiology, FGFR3 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…

2026 Achondroplasia strategy: epidemiology, FGFR3 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…

2026 Cleidocranial dysplasia strategy: epidemiology, RUNX2 biology, clinical competition, recent deals, unmet need and market attractiveness.